SCHEMBL6541691

SCHEMBL6541691

CCN(CC)CCOc1cc(NS(=O)(=O)c2ccc(OC)c(OC)c2)ccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.60
HTT P42858 3/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
ALDH1A1 P00352 7/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
PKM P14618 3/20 0.56
TSHR P16473 3/20 0.56
NPSR1 Q6W5P4 1/20 0.56
GAA P10253 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
FABP4 P15090 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAPT P10636 5/20 0.53
XBP1 P17861 2/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 1/20 0.53
CA12 O43570 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542791 0.89 LMNA (0.63) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6541986 0.86 UTS2R (0.48) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6541406 0.84 LMNA (0.56) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6542664 0.84 LMNA (0.64) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6542907 0.84 UTS2R (0.60) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6542118 0.80 UTS2R (0.57) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6541397 0.78 LMNA (0.64) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6541579 0.77 LMNA (0.42) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6176023 0.77 THRA (0.46) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL6542745 0.77 LMNA (0.63) LMNAHTTSMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR LMNA 4591/4885HTT 2297/4885SMN1; SMN2 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.